Novo Nordisk在印度发射Ozempic2型糖尿病,提供血糖控制、体重减退和心脏/婴儿保护。 Novo Nordisk launches Ozempic in India for type 2 diabetes, offering blood sugar control, weight loss, and heart/kidney protection.

Novo Nordisk在印度为2型无节制糖尿病患者推出Ozempic(semaglutide), 通过预先填充的笔每周提供三剂注射剂量。 Novo Nordisk has launched Ozempic (semaglutide) in India for patients with uncontrolled type 2 diabetes, offering three weekly injectable doses through pre-filled pens. 药价在2 200至2 794之间, 不仅用于血糖控制, 也用于减肥及降低心血管和肾脏风险。 Priced between ₹2,200 and ₹2,794 per week, the drug is approved not only for blood sugar control but also for weight loss and reducing cardiovascular and kidney risks. 此次推广紧随司美格鲁肽专利于2026年3月到期前，目标是印度日益加剧的糖尿病和肥胖负担，影响超过一亿人。 The rollout comes just ahead of semaglutide’s patent expiry in March 2026 and targets India’s escalating diabetes and obesity burden, affecting over 100 million people. 提供在处方上,Ozempic反映了全球日益转向GLP-1疗法,现在被世界卫生组织认可为高危患者. Available by prescription, Ozempic reflects the growing global shift toward GLP-1 therapies, now recognized by the WHO for high-risk patients.